Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 5/20 | 0.69 |
| ▸ | CA2 | P00918 | 5/20 | 0.69 |
| ▸ | CA12 | O43570 | 4/20 | 0.69 |
| ▸ | CA9 | Q16790 | 4/20 | 0.69 |
| ▸ | CA14 | Q9ULX7 | 4/20 | 0.69 |
| ▸ | CA7 | P43166 | 3/20 | 0.69 |
| ▸ | XDH | P47989 | 2/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.57 |
| ▸ | LMNA | P02545 | 3/20 | 0.57 |
| ▸ | GAA | P10253 | 2/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.57 |
| ▸ | GFER | P55789 | 1/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.57 |
| ▸ | RELA | Q04206 | 1/20 | 0.57 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.57 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 4/20 | 0.56 |
| ▸ | HPGD | P15428 | 3/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29550817 | 0.85 | CA1 (0.69) | CA1CA2CA12CA9CA14 | |
| SCHEMBL382159 | 0.85 | CA1 (0.69) | CA1CA2CA12CA9CA14 | |
| SCHEMBL12151586 | 0.84 | NOTUM (0.64) | CA1CA2CA12CA9CA14 | |
| SCHEMBL6507896 | 0.82 | CA12 (0.46) | CA1CA2CA12CA9CA14 | |
| Methyl Protocatechuate SCHEMBL29360855 | 0.82 | CA1 (1.00) | CA1CA2CA12CA9CA14 | |
| Methyl Protocatechuate SCHEMBL38624 | 0.82 | CA1 (1.00) | CA1CA2CA12CA9CA14 | |
| SCHEMBL15099889 | 0.82 | CA1 (0.77) | CA1CA2CA12CA9CA14 | |
| SCHEMBL205089 | 0.81 | NOTUM (0.60) | CA1CA2CA12CA9CA14 | |
| SCHEMBL851742 | 0.81 | KDM4E (0.58) | CA1CA2CA12CA9CA14 | |
| SCHEMBL2390790 | 0.80 | CA12 (0.72) | CA1CA2CA12CA9CA14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 567 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9604929-B2 | Functionalized carbon nanoparticles and functional polymer fibers prepared using the same | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2017-03-28 | — | — | US | claimed |
| US-20150204009-A1 | FUNCTIONALIZED CARBON NANOPARTICLES AND FUNCTIONAL POLYMER FIBERS PREPARED USING THE SAME | KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION (KR) | 2015-07-23 | — | — | US | claimed |
| EP-4748839-A1 | POLYCYCLIC COMPOUND AND USE THEREOF | CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang) Co., Ltd. (CN) | 2026-05-27 | — | — | EP | disclosed |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | LEUKOS BIOTECH S L (ES) | 2026-05-21 | — | — | US | disclosed |
| WO-2026098560-A2 | BENZENE-CONTAINING POLYCYCLIC DERIVATIVE MODULATOR, PREPARATION METHOD THEREFOR AND USE THEREOF | 上海翰森生物医药科技有限公司 | 2026-05-15 | — | — | WO | disclosed |
| EP-4688750-A1 | SUBSTITUTED INDAZOLE PROPIONIC ACID DERIVATIVE COMPOUNDS AND USES THEREOF AS AMPK ACTIVATORS | Pfizer Inc. (US) | 2026-02-11 | — | — | EP | disclosed |
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CEDILLA THERAPEUTICS INC (US) | 2026-02-05 | — | — | US | disclosed |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | LEUKOS BIOTECH, S.L. (ES) | 2026-02-03 | — | — | US | disclosed |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | REGENT OF THE UNIV OF MICHIGAN (US) | 2026-01-29 | — | — | US | disclosed |
| EP-4076460-B1 | 1,4-DIHYDRO-2H-SPIRO[ISOQUINOLINE-3,4'-PIPERIDINE DERIVATIVES AS PRMT5 INHIBITORS FOR THE TREATMENT OF CANCER | MERCK SHARP & DOHME LLC (US) | 2026-01-21 | — | — | EP | disclosed |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | UNIV MICHIGAN (US) | 2026-01-08 | — | — | US | disclosed |
| WO-2004089874-A1 | BIPHENYL CARBOXYLIC AMIDE P38 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION (US) | 2004-10-21 | — | — | WO | disclosed |
| WO-2004041285-A1 | ANTIINFLAMMATION AGENTS | AMGEN INC. (US) | 2004-05-21 | — | — | WO | disclosed |
| US-20040097485-A1 | Antiinflammation agents | TULARIK INC. | 2004-05-20 | — | — | US | disclosed |
| CN-1481376-A | HYDROXYBENZAMIDE DERIVATIVES AS FACTOR XA INHIBITORS | ���ĵ�˹ҩ��¹�����˾ | 2004-03-10 | — | — | CN | disclosed |
| EP-1349847-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | Aventis Pharma Deutschland GmbH (DE) | 2003-10-08 | — | — | EP | disclosed |
| WO-2003068749-A1 | VANILLOID RECEPTOR MODULATORS | GLAXO GROUP LIMITED (GB) | 2003-08-21 | — | — | WO | disclosed |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2002-12-26 | — | — | US | disclosed |
| WO-2002051831-A1 | OXYBENZAMIDES DERIVATIVES AS FACTOR XA INHIBITORS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-07-04 | — | — | WO | disclosed |
| EP-1217000-A1 | Inhibitors of factor Xa and factor VIIa | Aventis Pharma Deutschland GmbH (DE) | 2002-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260034123-A1 | CDK2 INHIBITORS AND METHODS OF USING THE SAME | CDK2, CDK1, CDK20 | CA1 2266/4885CA2 1909/4885CA12 2818/4885 |
| US-20260138974-A1 | POTENT AND SELECTIVE COMPOUNDS AS SEROTONIN 1B RECEPTOR MODULATORS | HTR3B, HTR1B, HTR1A | CA1 2941/4885CA2 2403/4885CA12 3845/4885 |
| US-12540133-B2 | Potent and selective compounds as serotonin 1B receptor modulators | HTR3B, HTR1A, HTR1B | CA1 3702/4885CA2 2854/4885CA12 4165/4885 |
| US-20260028354-A1 | TETRAHYDRONAPHTHALENE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, ESRRB | CA1 1445/4885CA2 1166/4885CA12 562/4885 |
| US-20020198195-A1 | New oxybenzamide derivatives useful for inhibiting factor Xa or VIIa | F9, F11, F5 | CA1 4325/4885CA2 2450/4885CA12 3684/4885 |
| US-20260007681-A1 | INDOLE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ESRRA, ESR2, AR | CA1 1137/4885CA2 871/4885CA12 716/4885 |
| US-20040097485-A1 | Antiinflammation agents | TNF, NFATC1, NFKBIA | CA1 4473/4885CA2 3538/4885CA12 4077/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.